Evidence map›Paper›PMID 42851484›Full record

ArticleFrontiers in immunology2026

Triple immunotherapy containing telitacicept for systemic lupus erythematosus complicated by multiple autoimmune diseases: a case report.

Yuqing Ge, Aifei Zhang, Longyan Qin, Didi Wang, Jiashun Zeng

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuqing GeDepartment of Rheumatology and Immunology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Aifei ZhangDepartment of Rheumatology and Immunology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Longyan QinDepartment of Rheumatology and Immunology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Didi WangDepartment of Rheumatology and Immunology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Jiashun ZengDepartment of Rheumatology and Immunology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SLE may occur simultaneously with or subsequently to other autoimmune diseases; such cases are called overlap syndromes. Cases of SLE overlapping with three or more autoimmune diseases are extremely rare, and there is no unified standard or consensus for treatment. We report a clinical case of a patient with SLE, immune-mediated necrotizing myopathy, Sjögren's syndrome, and psoriasis. After treatment with a triple immunosuppressive regimen containing telitacicept, the patient achieved a satisfactory therapeutic response. As the first dual-pathway inhibitor targeting BLyS/APRIL, telitacicept demonstrated potential in the treatment of this complex overlap syndrome, suggesting a promising application prospect in patients with multiple coexisting autoimmune diseases.

Indexed as

Autoimmune DiseasesImmunosuppressive AgentsImmunotherapyLupus Erythematosus, SystemicFemaleHumansPsoriasisRecombinant Fusion ProteinsSjogren's SyndromeTreatment OutcomeImmunosuppressive AgentsRecombinant Fusion ProteinstelitaciceptBLyS/APRILimmune-mediated necrotizing myopathypsoriasisSjögren’s syndromesystemic lupus erythematosustelitacicept

Identifiers

PMID42851484
PMCPMC13646162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.